IPP Bureau

AYUSH minister Sonowal exhorts researchers to explore Indian traditional medicine
AYUSH minister Sonowal exhorts researchers to explore Indian traditional medicine

By IPP Bureau - September 21, 2021

Assam is home to more than 1,700 species of medicinal plants

U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar
U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar

By IPP Bureau - September 21, 2021

It becomes the first ophthalmology biosimilar to gain FDA approval in the United States

HUTCHMED initiates a Japan bridging study to Support Surufatinib
HUTCHMED initiates a Japan bridging study to Support Surufatinib

By IPP Bureau - September 21, 2021

Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan

Pfizer and BioNTech’s Covid-19 vaccine safe for children aged 5 to 11: study
Pfizer and BioNTech’s Covid-19 vaccine safe for children aged 5 to 11: study

By IPP Bureau - September 21, 2021

In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year

Technology to distinguish between bacterial and viral infections cleared
Technology to distinguish between bacterial and viral infections cleared

By IPP Bureau - September 21, 2021

MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes

AAV Production system enables scalable gene therapy workflows
AAV Production system enables scalable gene therapy workflows

By IPP Bureau - September 21, 2021

New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments

Glenmark receives ANDA approval for treatment of acne
Glenmark receives ANDA approval for treatment of acne

By IPP Bureau - September 21, 2021

Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%

AstraZeneca to set up API facility in Ireland at an investment of US $ 360 million
AstraZeneca to set up API facility in Ireland at an investment of US $ 360 million

By IPP Bureau - September 21, 2021

The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes

Lincoln Pharma plans to launch Cephalosporin product portfolio soon
Lincoln Pharma plans to launch Cephalosporin product portfolio soon

By IPP Bureau - September 21, 2021

Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others

RxDx Healthcare receives NABL accreditation
RxDx Healthcare receives NABL accreditation

By IPP Bureau - September 20, 2021

RxDx is a chain of primary care driven multispecialty healthcare clinics with two main branches situated in Whitefield and Malleswaram in Bengaluru

Qardio’s remote patient cardiac monitoring service launched
Qardio’s remote patient cardiac monitoring service launched

By IPP Bureau - September 20, 2021

It is the first-ever fully remote end-to-end Remote Patient Monitoring (RPM) service to include cardiac arrhythmia analysis in a single, intuitive platform

U.S. FDA concludes inspection of Lupin’s Goa facility with seven observations
U.S. FDA concludes inspection of Lupin’s Goa facility with seven observations

By IPP Bureau - September 20, 2021

The company said in a regulatory filing that it was confident of addressing the observations satisfactorily

Imfinzi plus chemotherapy tripled patient survival at 3 years
Imfinzi plus chemotherapy tripled patient survival at 3 years

By IPP Bureau - September 20, 2021

The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting

Novartis’ Kisqali data indicates longest median survival in advanced breast cancer
Novartis’ Kisqali data indicates longest median survival in advanced breast cancer

By IPP Bureau - September 20, 2021

With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting

CDSCO approves Exablate 4000 for patients living with Parkinson’s disease
CDSCO approves Exablate 4000 for patients living with Parkinson’s disease

By IPP Bureau - September 20, 2021

The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain

Latest Stories

Interviews

Packaging